Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains

Medical Mycology

Volumn 47, Issue 2, 2009, Pages 137-143

  Panizo, María Mercedes ^a   Reviákina, Vera ^a   Dolande, Maribel ^a   Selgrad, Sofía ^a  

^a Instituto Nacional de Higiene Rafael Rangel   (Venezuela)

Author keywords

Candida spp; In vitro antifungal susceptibility testing; Resistance; Surveillance

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; FEMALE; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; YEAST;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; INFANT; ITRACONAZOLE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POPULATION SURVEILLANCE; PYRIMIDINES; TRIAZOLES; VENEZUELA; YOUNG ADULT;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 59249090688     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802144339     Document Type: Article

References (33)

1. Hazen, KC. (1995) New and emerging yeast pathogens. Clin Microbiol Rev, 8, pp. 462-478.
2. Clark, TA and Hajjeh, RA. (2002) Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis, 15, pp. 569-574.
3. Eggimann, P., Garbino, J. and Pittet, D. (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis, 3, pp. 685-702.
4. Perlroth, J., Choi, B. and Spellberg, B. (2007) Nosocomial fungal infections: Epidemiology, diagnosis, and treatment. Med Mycol, 45, pp. 321-346.
5. Wingard, JR. (1995) Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis, 20, pp. 115-125.
6. St-Germain, G., Laverdiere, M., Pelletier, R. Bourgault, A-M et al. (2001) Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol, 39, pp. 949-953.
7. Lodder, J. (1970) The Yeasts. A Taxonomic Study, American Elsevier Publishing Company, New York
8. Barnett, JA, Payne, RW and Yarrow, D. (1979) A Guide to Identifying and Classifying Yeasts, Cambridge University Press, Cambridge
9. McGinnis, M. (1980) Laboratory Handbook of Medical Mycology, Academic Press Inc, New York
10. Haley, LD and Callaway, CS. (1978) Laboratory Methods in Medical Mycology, US Department of Health, Education and Welfare. Centre for Diseases Control, Atlanta, GA
11. Drouhet, E., Dupont, B., Improvisi, L., Viviani, MA and Tortorano, AM. (1986) In vitro and in vivo evaluation of antifungal agents, pp. 31-49. Elsevier science Publishers, Amsterdam
12. Reviakina, V., Mendoza, M. and Panizo, M. (2004) Estandarizacion y aplicacion practica del metodo de disco difusion para Candida albicans frente a fluconazol. Antibiot Infecc, 12, pp. 31-44.
13. National Committee for Clinical Laboratory Standards (2002) Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A2, Wayne, PA
14. Pfaller, MA, Boyken, I. Messer, SA et al. (2005) Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol, 43, pp. 5208-5213.
15. Espinel-Ingroff, A., Barchiesi, F. Cuenca-Estrella, M. et al. (2005) International and multicentric comparison of EUCAST and CLSI M27-A2 broth microdilution method for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol, 43, pp. 3884-3889.
16. Pfaller, MA, Messer, SA, Karlsson, A. and Bolmstrom, A. (1998) Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol, 36, pp. 2586-2589.
17. Pfaller, MA, Diekema, DJ Jones, RN et al. (1997) International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol; 39, 2001, pp. 3254-3259.
18. Pfaller, MA, Diekema, DJ, Messer, SA, Boyken, L. and Hollis, RJ. (2001) Activities of fluconazole and voriconazole againts 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: Report from the ARTEMIS Global Antifungal Susceptibility Program. J Clin Microbiol; 41, 2003, pp. 1440-1446.
19. Messer, SA, Jones, RN and Fritsche, TR. (2003) International surveillance of Candida spp. and Aspergillus spp.: Report from SENTRY antimicrobial Surveillance program. J Clin Microbiol; 44, 2006, pp. 1782-1787.
20. Capoor, MR, Nair, D. Deb, M. et al. (2005) Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital. Jpn J Infect Dis, 58, pp. 344-348.
21. Mujica, MT, Finquelievich, JL, Jewtuchowicz, V. and Iovannitti, CA. (1999) Prevalencia de Candida albicans y Candida no albicans en diferentes muestras clinicas. Periodo -2001. Rev Arg Microbiol; 36, 2004, pp. 107-112.
22. Hajjeh, RA, Sofair, AN Harrison, LH et al. (1998) Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from to 2000 in a population-based active surveillance program. J Clin Microbiol; 42, 2004, pp. 1519-1527.
23. Pfaller, MA, Diekema, DJ, Jones, RN, Messer, SA, Hollis, RJ and and the SENTRY Participants Group (2002) Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol, 40, pp. 852-856.
24. Rodero, L., Davel, G., Soria, M., Vivot, W., Cordoba, S., Canteros, CE, Saporiti, A. and y participantes del grupo, EMIFN. (2005) Estudio multicentrico de fungemias por levaduras en la Republica Argentina. Rev Arg Microbiol, 37, pp. 189-195.
25. Kao, AS, Brandt, ME Pruitt, WR et al. (1999) The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. Clin Infect Dis, 29, pp. 1164-1170.
26. Saiman, L., Ludington, E. Pfaller, M. et al. (2000) Risk factors for candidemia in neonatal intensive care unit patients. Pediatr Infect Dis, 19, pp. 319-324.
27. Rowen, JL and Tate, JM. (1998) Management of neonatal candidiasis. Neonatal Candidiasis Study Group. Pediatr Infect Dis, 17, pp. 1007-1011.
28. Waggoner-Fountain, LA, Walker, MW Hollis, RJ et al. (1996) Vertical and horizontal transmission of unique Candida species to premature newborns. Clin Infect Dis, 22, pp. 803-808.
29. Weems Jr, JJ (1992) Candida parapsilosis: Epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis, 14, pp. 756-766.
30. Ascioglu, S., Rex, JH De Pauw, B. et al. (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis, 34, pp. 7-14.
31. Pfaller, MA, Messer, SA, Hollis, RJ, Jones, RN and Diekema, DJ. (2002) In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6.970 clinical isolates of Candida spp. Antimicrob Agents Chemother, 46, pp. 1723-1727.
32. Perea, S. and Patterson, TF. (2002) Antifungal resistance in pathogenic fungi. Clin Infect Dis, 35, pp. 1073-1080.
33. Skrodeniene, E., Dambrauskiene, A. and Vitkauskiene, A. (2006) Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital. Medicina (Kaunas), 42, pp. 294-299.